Eming S A
Klinik und Poliklinik für Dermatologie und Venerologie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Hautarzt. 2018 Nov;69(11):885-891. doi: 10.1007/s00105-018-4256-9.
Fibrosis is a common symptom of a variety of skin disorders of diverse entity. The cellular and molecular pathophysiology of fibrosis development is unresolved and current treatment options are not sufficient. Tissue fibrosis leads to increased tissue stiffness, impaired organ function, decline of quality of life and ultimately increased morbidity and mortality. Epidemiologic studies indicate that nearly 45% of all deaths in the western world are associated with tissue fibrosis in diverse organs. Only few recently approved treatment options specifically target the process of fibrogenesis. The development of novel and efficient therapies is urgently needed, and at the same time provides a major challenge but also an opportunity to contribute to the advancement of this unresolved medical problem. This article highlights recent insights in the developments on tissue fibrosis with a focus on immunoregulatory mechanisms.
纤维化是多种不同类型皮肤疾病的常见症状。纤维化发展的细胞和分子病理生理学尚未明确,目前的治疗选择也并不充分。组织纤维化会导致组织硬度增加、器官功能受损、生活质量下降,并最终增加发病率和死亡率。流行病学研究表明,西方世界近45%的死亡与不同器官的组织纤维化有关。最近仅有少数获批的治疗方案专门针对纤维生成过程。迫切需要开发新的有效疗法,这同时也带来了重大挑战,但也为推动解决这一尚未解决的医学问题提供了机遇。本文重点介绍了组织纤维化发展方面的最新见解,尤其关注免疫调节机制。